Biosig Technologies Stock News

Despite numerous positive updates around its PURE EP segment, the market is agnostic in directional movements on the chart. Whilst the muddy waters on its PURE EP economics have been somewhat cleared,

BioSig Technologies Inc plans to kick off a national commercial launch campaign for its PURE EP System on July 1, 2022 following multiple initiatives to accelerate its transition from limited mark

BioSig Technologies Inc drew an ‘Outperform' rating from Noble Capital, which noted that "stronger commercialization efforts” are underway for the company's PURE (Precise Uninterrupted Real-time

BioSig Technologies, Inc. (NASDAQ:BSGM) CEO Kenneth Londoner said the company has made great strides on multiple fronts as it accelerates commercial momentum for developing a national installed base o

Company's conference program to include physician presentations and technology demonstrations, including features of its newly released PURE EP(TM) Nova-5 Software Company's conference program to incl

Westport, CT, April 07, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal process

BioSig Technologies Inc has announced the completion of its previously announced underwritten public offering of 2,611,739 shares of its common stock at a price to the public of $1.15 per share for p

BioSig Technologies Inc announced that it has agreed to sell $3 million of its common stock and warrants to a family office, which the company said has deep expertise in small-cap emerging growth inv

Medical technology company, BioSig Technologies (BSGM) appoints John Sieckhaus as COO.Most recently, Mr

BioSig Technologies Inc. has announced that John Sieckhaus will be joining the company as chief operating officer.

BioSig Technologies Inc, the medtech group, has announced another boost for its heart monitoring technology, revealing that the US Patent Office had awarded patent claims for its PURE EP noise-filteri

Biosig Technologies Inc (BSGM) shares closed today at 2.0% above its 52 week low of $2.03, giving the company a market cap of $73M. The stock is currently down 7.2% year-to-date, down 60.8% over the past 12 months, and down 69.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 55.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 1.5% lower than its 5-day moving average, 10.7% lower than its 20-day moving average, and 23.8% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -6643.5% The company's stock price performance over the past 12 months lags the peer average by -3449.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Biosig Technologies Inc (BSGM) shares closed today at 1.5% above its 52 week low of $2.05, giving the company a market cap of $74M. The stock is currently down 4.9% year-to-date, down 58.6% over the past 12 months, and down 68.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 64.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1224.7% The company's stock price performance over the past 12 months lags the peer average by -4396.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Westport, CT, Jan. 07, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM ) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company would be presenting at the 27th Annual International Atrial Fibrillation Symposium on January 13-15, 2022. Clinical observations collected with BioSig''s PURE EP System will be presented by DJ Lakkireddy, M.D., Kansas City Heart Rhythm Institute at HCA Midwest Health during Spotlight Session : Complex AF Case Study Utilizing a New Standard in Signal Processing on January 13, 2022, from 8:30-9:30 AM ET. "Dr. Lakkireddy is highly regarded for his passionate commitment to those suffering from complex arrhythmias and for his leadership in the field of electrophysiology, and we are thrilled to have him represent our technology at this benchmark industry event. We would like to thank the course directors, Drs.

PURE EP (TM) System to be highlighted in a Spotlight Session by DJ Lakkireddy, M.D., Kansas City Heart Rhythm Institute at HCA Midwest Health PURE EP (TM) System to be highlighted in a Spotlight Sessi